FDA.reportPublic FDA data

tazarotene 1 MG/ML Topical Foam

RxCUI
1293451
RxNorm name
tazarotene 1 MG/ML Topical Foam
Display name
tazarotene 1 MG/ML Topical Foam
Full name
tazarotene 1 MG/ML Topical Foam
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:15

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FABIORTAZAROTENEMayne Pharmaae0afed7-1d60-45fd-a08b-8db0946185212026-03-03Warnings, Adverse reactionsExact identifier
rxcui: 1293451
tazaroteneTAZAROTENEMayne Pharma Inc.0e337598-f589-483f-a2ae-be7c319d74542024-06-04Warnings, Adverse reactionsExact identifier
rxcui: 1293451

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
ae0afed7-1d60-45fd-a08b-8db094618521tazarotene 0.1 % Topical FoamSY7These highlights do not include all the information needed to use FABIOR Foam safely and effectively. See full prescribing information for FABIOR Foam. FABIOR (tazarotene) Foam, 0 .1%, for topical use Initial U.S. Approval: 199720260303
ae0afed7-1d60-45fd-a08b-8db094618521tazarotene 0.1 % Topical FoamPSN7These highlights do not include all the information needed to use FABIOR Foam safely and effectively. See full prescribing information for FABIOR Foam. FABIOR (tazarotene) Foam, 0 .1%, for topical use Initial U.S. Approval: 199720260303
ae0afed7-1d60-45fd-a08b-8db094618521tazarotene 1 MG/ML Topical FoamSCD7These highlights do not include all the information needed to use FABIOR Foam safely and effectively. See full prescribing information for FABIOR Foam. FABIOR (tazarotene) Foam, 0 .1%, for topical use Initial U.S. Approval: 199720260303
0e337598-f589-483f-a2ae-be7c319d7454tazarotene 0.1 % Topical FoamPSN3These highlights do not include all the information needed to use Tazarotene Foam safely and effectively. See full prescribing information for Tazarotene Foam. Tazarotene Foam, 0 .1%, for topical use Initial U.S. Approval: 199720240604
0e337598-f589-483f-a2ae-be7c319d7454tazarotene 1 MG/ML Topical FoamSCD3These highlights do not include all the information needed to use Tazarotene Foam safely and effectively. See full prescribing information for Tazarotene Foam. Tazarotene Foam, 0 .1%, for topical use Initial U.S. Approval: 199720240604
0e337598-f589-483f-a2ae-be7c319d7454tazarotene 0.1 % Topical FoamSY3These highlights do not include all the information needed to use Tazarotene Foam safely and effectively. See full prescribing information for Tazarotene Foam. Tazarotene Foam, 0 .1%, for topical use Initial U.S. Approval: 199720240604